280 related articles for article (PubMed ID: 26779490)
1. Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma.
Salvianti F; Orlando C; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Pinzani P
Front Mol Biosci; 2015; 2():76. PubMed ID: 26779490
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric analysis of cell-free DNA in melanoma patients.
Salvianti F; Pinzani P; Verderio P; Ciniselli CM; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Orlando C
PLoS One; 2012; 7(11):e49843. PubMed ID: 23209607
[TBL] [Abstract][Full Text] [Related]
3. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.
Chimonidou M; Strati A; Malamos N; Georgoulias V; Lianidou ES
Clin Chem; 2013 Jan; 59(1):270-9. PubMed ID: 23136251
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
5. Circulating free DNA integrity index and promoter methylation of tumor suppressor gene P16, DAPK and RASSF1A as a biomarker for oropharyngeal squamous cell carcinoma.
Kumari S; Mishra S; Anand N; Hadi R; Rastogi M; Husain N
Pathol Res Pract; 2023 Jun; 246():154489. PubMed ID: 37150134
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia.
Salvianti F; Inversetti A; Smid M; Valsecchi L; Candiani M; Pazzagli M; Cremonesi L; Ferrari M; Pinzani P; Galbiati S
Placenta; 2015 Sep; 36(9):996-1001. PubMed ID: 26183647
[TBL] [Abstract][Full Text] [Related]
9. Increased Sensitivity of Detection of
Friedemann M; Horn F; Gutewort K; Tautz L; Jandeck C; Bechmann N; Sukocheva O; Wirth MP; Fuessel S; Menschikowski M
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503269
[TBL] [Abstract][Full Text] [Related]
10. Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors.
van Zogchel LMJ; Lak NSM; Verhagen OJHM; Tissoudali A; Gussmalla Nuru M; Gelineau NU; Zappeij-Kannengieter L; Javadi A; Zijtregtop EAM; Merks JHM; van den Heuvel-Eibrink M; Schouten-van Meeteren AYN; Stutterheim J; van der Schoot CE; Tytgat GAM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34820594
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma.
Bos MK; Kraan J; Starmans MPA; Helmijr JCA; Verschoor N; De Jonge MJA; Joosse A; van der Veldt AAM; Te Boekhorst PAW; Martens JWM; Sleijfer S; Wilting SM
Mol Oncol; 2024 May; ():. PubMed ID: 38790134
[TBL] [Abstract][Full Text] [Related]
12. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients.
Ponti G; Maccaferri M; Manfredini M; Kaleci S; Mandrioli M; Pellacani G; Ozben T; Depenni R; Bianchi G; Pirola GM; Tomasi A
Clin Chim Acta; 2018 Apr; 479():14-19. PubMed ID: 29309771
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Analysis of the
Zhang N; Liu Z; Li K; Xing X; Long C; Liu F; She B; Che N
J Oncol; 2023; 2023():5888844. PubMed ID: 36691467
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
17. Impact of
Jezkova E; Zubor P; Kajo K; Grendar M; Dokus K; Adamkov M; Lasabova Z; Plank L; Danko J
Oncol Lett; 2017 Jul; 14(1):758-766. PubMed ID: 28693231
[TBL] [Abstract][Full Text] [Related]
18. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment.
Ntzifa A; Londra D; Rampias T; Kotsakis A; Georgoulias V; Lianidou E
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885084
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic significance of cell-free DNA concentration in melanoma.
Váraljai R; Elouali S; Lueong SS; Wistuba-Hamprecht K; Seremet T; Siveke JT; Becker JC; Sucker A; Paschen A; Horn PA; Neyns B; Weide B; Schadendorf D; Roesch A
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):387-395. PubMed ID: 32569440
[TBL] [Abstract][Full Text] [Related]
20. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
